Xenolol Plus Tablet SR is a sustained-release formulation combining Propranolol 40 mg and Flunarizine 10 mg, designed for the management of various cardiovascular and neurological conditions. Propranolol, a non-selective beta-adrenergic blocker, exerts its therapeutic effects by reducing heart rate, myocardial contractility, and cardiac output, thereby lowering blood pressure and preventing angina pectoris. It is also effective in the prophylaxis of migraine and the management of certain arrhythmias. Flunarizine, a calcium channel blocker with antihistaminic properties, acts by inhibiting the influx of calcium ions into vascular smooth muscle and neurons, which helps prevent cerebral vasospasm and reduces neuronal excitability. This combination is particularly beneficial in patients requiring both cardiovascular control and migraine prophylaxis or vestibular disorder management. The sustained-release formulation ensures a steady plasma concentration, enhancing patient compliance and minimizing side effects. Xenolol Plus is indicated for hypertension, angina pectoris, migraine prophylaxis, and vestibular disorders such as vertigo. Caution is advised in patients with asthma, bradycardia, or hepatic impairment. Common adverse effects include fatigue, dizziness, and gastrointestinal discomfort. Use under medical supervision is recommended to optimize therapeutic outcomes and monitor for potential drug interactions.